Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $592
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad maintains an Overweight rating on IDEXX Laboratories (NASDAQ:IDXX) and raises the price target from $590 to $592.
November 02, 2023 | 3:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on IDEXX Laboratories and raises the price target from $590 to $592.
The news is directly related to IDEXX Laboratories and is likely to have a positive impact on its stock price in the short term. The Overweight rating indicates that Barclays expects the company's stock to outperform the market, and the raised price target suggests that they see further upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100